Slingshot members are tracking this event:
Complete Remission Rate of 90%: China-based CAR-T Cell Therapy Achieves Breakthrough Clinical Trial Results
Do you think this event is important to the companies below? How will it affect their stock price?
The clinical trial was conducted in strict accordance with clinical ethical standards and monitored independently by a third-party clinical research organization. All patient expenses incurred by the CAR-T trial were reimbursed by ICT. Nine out of the ten patients achieved complete remission, and the minimal residual disease (MRD) in 8 patients turned negative, a significant indication of curative effect. Both the complete remission rate of 90% and the MRD-negative rate of 80% out-performed the best results recorded worldwide to date.All ten patients, ranging in age from 17 to 57, suffered from relapsed or refractory B lymphocytic leukemia and were expected to live only several months. The tenth and final patient is a 17-year-old female who enrolled in the CAR-T clinical trial in March of this year. After collecting her blood, researchers performed a genetic transformation of her common T-cells to express a molecule called Chimeric Antigen Receptor (CAR). Similar to GPS, CAR can guide specific T-cells to track, identify and kill malignant tumor cells. Through the application of this technology, common T-cells were transformed into "cancer fighting" CAR-T cells.In early April 2016, the transformed CAR-T cells were infused into the body of the patient, and the 'cytokine storm' took place as the research team had expected. As the CAR-T cells rapidly proliferated in the patient's body and released a large number of cytokines, the patient experienced symptoms that included fever, muscle pain and hypoxemia. These symptoms indicated that the introduction of CAR-T cells was having a positive effect. The subsequent test results showed that she was in complete remission and she was identified as MRD-negative.Innovative Cellular Therapeutics, in collaboration with the First Affiliated Hospital of Zhejiang University, achieved success in the evolution of CAR-T therapy. ICT is conducting clinical trials on relapsed and refractory acute lymphocytic leukemia in seven other hospitals across China and has completed the trial and initial data collection of 23 patients suffering from an advanced stage of the disease. Twenty patients, or 87% of the total trial population, enjoyed complete remission of leukemia.Before the trial, only three firms in the world (Novartis, Juno and Kite Pharma), all based in the U.S., have developed similar levels of CAR-T therapy for leukemia. ICT, a Chinese firm, has now joined that distinguished group to become one of the global leaders in the application of CAR-T therapy.
Slingshot Insights Explained
May 06, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Car-t Therapy, Leukemia, Cytokines